The diagnostic performance of antimullerian hormone for polycystic ovarian syndrome and polycystic ovarian morphology
- 24 December 2022
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (4) , 1083-1090
Abstract
Purpose The diagnosis of polycystic ovary syndrome (PCOS) remains a challenge to clinicians due to heterogeneous clinical presentation and diagnostic criteria. This study investigated the utilization of Anti-Müllerian hormone (AMH) alone or replacing polycystic ovarian morphology (PCOM) in the PCOS diagnostic criteria. Methods A total of 401 women were categorised as PCOS (n:154), nonPCOS with polycystic ovarian morphology (PCOM) (n:105), and nonPCOS with normal ovarian morphology (NOM) (n:142). First, the diagnostic performance of AMH for PCOS diagnosis in Rotterdam, Androgen Excess Society, and National Institutes of Health (NIH) criteria was analyzed. Second, AMH was used instead of PCOM in Rotterdam criteria and we searched diagnostic performance for PCOS phenotypes. Results AMH levels were positively correlated with LH, testosterone, hirsutism score, menstrual cycle length, and antral follicle count (p < 0.05). AMH alone had specificity and sensitivity for PCOS diagnosis were 84.9% and 72.4% in Rotterdam (AUC: 0.866); 84.4% and 72% in Androgen Excess Society (AUC: 0.857); 83.3% and 66.4% in National Institute of Health criteria (AUC: 0.825). AMH alone had satisfactory diagnostic potential for phenotype A, but not other phenotypes. The replacement of PCOM with AMH in Rotterdam criteria had a high diagnostic potential for PCOS (AUC: 0.934, sensitivity:97.4%, specificity: 90.67%). Phenotype A and phenotype D were diagnosed with 100% sensitivity and 94.5% specificity. Phenotype C was recognised with 96.15% sensitivity and 94.5% specificity. Conclusion AMH may be used with high diagnostic accuracy instead of PCOM in the Rotterdam PCOS criteria.Keywords
All Related Versions
This publication has 32 references indexed in Scilit:
- Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenismJournal of Assisted Reproduction and Genetics, 2012
- The journey from the old to the new AMH assay: how to avoid getting lost in the valuesReproductive BioMedicine Online, 2011
- Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovariesHuman Reproduction, 2011
- Antimüllerian hormone and polycystic ovary syndromeFertility and Sterility, 2011
- Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndromeWiener klinische Wochenschrift, 2010
- Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS)Fertility and Sterility, 2010
- The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force reportFertility and Sterility, 2009
- Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levelsAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndromeEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2007
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndromeFertility and Sterility, 2004